16 However, despite these improvements in CVD risk factors and modest weight loss, reductions in cardiovascular outcomes were not demonstrated, so the trial was discontinued at a median follow up of 9.6 years following a futility analysis
What are the benefits of GLP-1
That could mean as many as 20 million Americans already are using GLP-1s, and subsequently benefiting from lower colon cancer risk
Metformin and tirzepatide target different pathways in glucose regulation and weight management, making them potentially synergistic when used together
Glucagon receptor-mediated effects introduce additional considerations: Potential for transient increases in heart rate (also observed with GLP-1R agonists) Theoretical risk of hyperglycaemia from glucagon signalling, though phase 2 trial data suggest this is counterbalanced by concurrent GLP-1R and GIPR agonism In phase 2 trials, the most commonly reported adverse events were gastrointestinal in nature, consistent with the class
Second, the liver enzyme CYP2E1 breaks down about 5-10% of the drug, resulting in the formation of a toxin known as NAPQI
